NATURETIN-2.5

Clinical safety rating: caution

Comprehensive clinical and safety monograph for NATURETIN-2.5 (NATURETIN-2.5).

How it works

Bendroflumethiazide is a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the kidney, reducing sodium and chloride reabsorption and promoting diuresis.

What the body does with it

Metabolism	Primarily hepatic via CYP450 enzymes; excreted renally as unchanged drug and metabolites.
Excretion	Renal excretion: approximately 95% as unchanged drug; biliary/fecal: <5%.
Half-life	Terminal elimination half-life: 6-9 hours; prolonged in renal impairment and in elderly patients.
Protein binding	Approximately 90% bound to plasma proteins (albumin).
Volume of Distribution	0.7-1.5 L/kg; indicates extensive distribution into tissues.
Bioavailability	Oral: approximately 50-70% due to first-pass metabolism.
Onset of Action	Oral: 1-2 hours.
Duration of Action	Oral: 12-24 hours; antihypertensive effect persists for up to 24 hours with once-daily dosing.

Classification & Brands

Dosing & administration

Hypertension: 2.5 mg orally once daily; may increase to 5 mg daily if needed. Edema: 2.5 to 10 mg orally once daily.

Dosage form	TABLET
Renal impairment	eGFR <30 mL/min: Use with caution; consider alternative diuretic. eGFR <15 mL/min: Avoid use.
Liver impairment	Mild to moderate impairment (Child-Pugh A/B): No adjustment necessary. Severe impairment (Child-Pugh C): Avoid use.
Pediatric use	Not recommended for pediatric use; safety and efficacy not established.
Geriatric use	Start at 2.5 mg orally once daily; titrate slowly due to increased risk of electrolyte imbalance and hypotension.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for NATURETIN-2.5 (NATURETIN-2.5).

Breastfeeding	Not recommended. Excreted in breast milk; M/P ratio not established. Potential for adverse effects in nursing infant, including electrolyte disturbances and hypotension.
Teratogenic Risk	Pregnancy Category D. First trimester: Associated with fetal anomalies including neural tube defects and cardiovascular malformations. Second and third trimesters: Risk of fetal renal dysfunction, oligohydramnios, and neonatal hypotension.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

No FDA black box warning.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Anuria","Hypersensitivity to bendroflumethiazide or sulfonamide-derived drugs","Severe renal impairment (CrCl <30 mL/min)","Hepatic coma or pre-coma"]

Clinical Precautions

Precautions

["Electrolyte disturbances: hypokalemia, hyponatremia, hypomagnesemia","Hyperuricemia and gout","Hypercalcemia","Orthostatic hypotension","May exacerbate diabetes mellitus","Sulfonamide allergy cross-reactivity","Photosensitivity","Systemic lupus erythematosus exacerbation"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

NATURETIN-2.5

Clinical safety rating: caution

Comprehensive clinical and safety monograph for NATURETIN-2.5 (NATURETIN-2.5).

How it works

What the body does with it

Metabolism	Primarily hepatic via CYP450 enzymes; excreted renally as unchanged drug and metabolites.
Excretion	Renal excretion: approximately 95% as unchanged drug; biliary/fecal: <5%.
Half-life	Terminal elimination half-life: 6-9 hours; prolonged in renal impairment and in elderly patients.
Protein binding	Approximately 90% bound to plasma proteins (albumin).
Volume of Distribution	0.7-1.5 L/kg; indicates extensive distribution into tissues.
Bioavailability	Oral: approximately 50-70% due to first-pass metabolism.
Onset of Action	Oral: 1-2 hours.
Duration of Action	Oral: 12-24 hours; antihypertensive effect persists for up to 24 hours with once-daily dosing.

Classification & Brands

Dosing & administration

Hypertension: 2.5 mg orally once daily; may increase to 5 mg daily if needed. Edema: 2.5 to 10 mg orally once daily.

Dosage form	TABLET
Renal impairment	eGFR <30 mL/min: Use with caution; consider alternative diuretic. eGFR <15 mL/min: Avoid use.
Liver impairment	Mild to moderate impairment (Child-Pugh A/B): No adjustment necessary. Severe impairment (Child-Pugh C): Avoid use.
Pediatric use	Not recommended for pediatric use; safety and efficacy not established.
Geriatric use	Start at 2.5 mg orally once daily; titrate slowly due to increased risk of electrolyte imbalance and hypotension.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for NATURETIN-2.5 (NATURETIN-2.5).

Breastfeeding	Not recommended. Excreted in breast milk; M/P ratio not established. Potential for adverse effects in nursing infant, including electrolyte disturbances and hypotension.
Teratogenic Risk	Pregnancy Category D. First trimester: Associated with fetal anomalies including neural tube defects and cardiovascular malformations. Second and third trimesters: Risk of fetal renal dysfunction, oligohydramnios, and neonatal hypotension.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

No FDA black box warning.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Anuria","Hypersensitivity to bendroflumethiazide or sulfonamide-derived drugs","Severe renal impairment (CrCl <30 mL/min)","Hepatic coma or pre-coma"]